We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
No comments yet, be the first to start the discussion!
Nov 30, 2022
Based on imaging and tumor marker reports, I believed letrozole worked very well in this case. We can preserve CDK 4/6 Inh. if the metastases show progression. Since the patient has no symptoms and we can not exclude lung metastasis, I do not agree with neck radiation too.
Jan 07, 2023
In view of the prolonged disease-free survival and good response to Letrozole, I will suggest continuing the current management and reserve CDK4/6 Inhb for progression. Radiation may not be of much use to us.
Jan 30, 2023
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.